Repros Therapeutics makes Androxal / Enclomiphene announcement.

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.